N-acetylcysteine trial for people at risk of Huntington’s disease
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign consent
- You are a Huntington’s gene expansion carrier with at least 39 CAG repeats
- You do not yet have clear movement signs of Huntington’s disease
- A doctor expects you may develop symptoms within about 10 years of joining
- You can provide a family member or other informant to confirm your health history
- You can safely do MRI scans and blood tests, and a study doctor says you are medically and mentally stable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a vitamin B3-like supplement, nicotinamide riboside, can help people with early to mid-stage Huntington's disease. You will be randomly assigned to take the supplement or a placebo to see if it slows the disease.
This study uses special brain imaging and memory/thinking tests to find early “markers” that can predict how Huntington’s disease will progress over time. You may qualify as someone with early-stage Huntington’s or as a healthy control, if you meet specific safety and scoring requirements.
This trial tests whether human neural stem cells are safe and tolerable for people with Huntington's disease. It involves a neurosurgical procedure to inject the cells into the brain, along with MRI scans and other monitoring.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
This study tests new ways to measure thinking and memory skills in people with Huntington's disease. It aims to find better tools for tracking the disease and could help you understand your cognitive changes.
This study tests whether a medication called pridopidine can help slow the progression of Huntington's disease symptoms in adults. Huntington's is a genetic disorder affecting movement, mood, and thinking, and this trial aims to see if pridopidine improves daily functioning and quality of life.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.